Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 3, 2018. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and does not contain financial performance data.
Material Changes
The filing details the Company's issued share capital as of August 31, 2018:
- Total Issued Shares: 5,374,922,551 Ordinary Shares of 25 pence each.
- Treasury Shares: 414,605,950 Ordinary Shares held in Treasury.
- Total Voting Rights: 4,960,316,601.
No comparative data for prior periods is included in this specific filing to determine material changes in share count.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document's sole purpose is to establish the denominator for shareholder notification calculations under FCA rules.
Investor Verification Checklist
- Verify the total number of voting rights (4,960,316,601) against the latest 20-F annual report to ensure consistency.
- Confirm the number of shares held in Treasury (414,605,950) to calculate the correct denominator for ownership threshold notifications.
- Check subsequent filings for any changes in share capital or treasury holdings since August 31, 2018.